{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:22:30Z","timestamp":1787653350296,"version":"build-2736575974"},"reference-count":155,"publisher":"Informa UK Limited","issue":"19","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,8,9]]},"DOI":"10.1080\/14796694.2026.2709201","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:31:40Z","timestamp":1785400300000},"page":"2347-2366","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience"],"prefix":"10.1080","volume":"22","author":[{"given":"Riddhi A.","family":"Babel","sequence":"first","affiliation":[{"name":"Value &amp; Implementation Outcomes Research, Oncology, Merck &amp; Co., Inc., Rahway, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen V.","family":"Liu","sequence":"additional","affiliation":[{"name":"Georgetown University","place":["Washington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Fan","sequence":"additional","affiliation":[{"name":"Value &amp; Implementation Outcomes Research, Oncology, Merck &amp; Co., Inc., Rahway, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur M.","family":"Amonkar","sequence":"additional","affiliation":[{"name":"Value &amp; Implementation Outcomes Research, Oncology, Merck &amp; Co., Inc., Rahway, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsidhar","family":"Velcheti","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Jacksonville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102693"},{"key":"e_1_3_5_4_1","unstructured":"American Cancer Society. Key statistics for lung cancer 2025 [updated January;October 2025]. Available from: https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/key-statistics.html"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-73389-6"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100492"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.585284"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2020.03.40"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100374"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2024.08.005"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-890"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.06.014"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1807704"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.1655"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.04.1678"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.21216"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02152-6"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-24-26"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14538"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.04.014"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032899"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-80301-9"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_209089"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126748"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.013"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32050274"},{"key":"e_1_3_5_28_1","unstructured":"\u00a9National Comprehensive Cancer Network Inc V.6. 2026 referenced with permission from the NCCN clinical practice guidelines in Oncology (NCCN guidelines\u00ae) for non-small cell lung cancer V.6. 2026. \u00a9 National Comprehensive Cancer Network Inc; 2026. All rights reserved. Accessed 2026 Jun 23. To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way. Vol. 6."},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00241"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.04.008"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01990"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab171"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2024.05.002"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1635626"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2023.2238544"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0078"},{"key":"#cr-split#-e_1_3_5_41_1.1","unstructured":"European Medicines Agency. Keytruda. 2025 [updated 2025 Dec 03"},{"key":"#cr-split#-e_1_3_5_41_1.2","unstructured":"cited 2026 Feb 18]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/keytruda#assessment-history"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"#cr-split#-e_1_3_5_43_1.1","unstructured":"Food and Drug Administration. FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC 2018 [updated 2018 Dec 14"},{"key":"#cr-split#-e_1_3_5_43_1.2","unstructured":"cited 2026 Feb 18]. Available from: https:\/\/www.fda.gov\/drugs\/fda-approves-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic-squamous-nsclc"},{"key":"#cr-split#-e_1_3_5_44_1.1","unstructured":"Food and Drug Administration. FDA grants regular approval for pembrolizumab in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLC 2018 [updated 2018 Aug 20"},{"key":"#cr-split#-e_1_3_5_44_1.2","unstructured":"cited 2026 February 18]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7216"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0167-7"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13903"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.59"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-015-1023-4"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx187"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0647"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15069"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2569856"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(25)00219-9"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0177"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1642"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.03.008"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-026-19138-7"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.740"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09843-3"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2342224"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03232-2"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1351995"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153809"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02895-1"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.1134"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.381"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1341084"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.06.010"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.04.001"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1177\/15330338211039676"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1442909"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04125-w"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.08.001"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114006"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz288"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.9111"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.343"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.321"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e15156"},{"issue":"9","key":"e_1_3_5_81_1","first-page":"100675","article-title":"Three-year Overall survival outcomes and correlative analyses in patients with NSCLC and high (50%-89%) versus very high (\u226590%) Programmed death-ligand 1 expression treated with first-line pembrolizumab or cemiplimab","volume":"5","author":"Ricciuti B","year":"2024","unstructured":"Ricciuti B, Elkrief A, Lin J, et al. Three-year Overall survival outcomes and correlative analyses in patients with NSCLC and high (50%-89%) versus very high (\u226590%) Programmed death-ligand 1 expression treated with first-line pembrolizumab or cemiplimab. JTO Clin Res Rep. 2024;5(9):100675.","journal-title":"JTO Clin Res Rep"},{"issue":"3","key":"e_1_3_5_82_1","first-page":"3","article-title":"Treatment patterns and clinical outcomes of patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitor monotherapy in the first-line setting in community-based practices in the United States","volume":"29","author":"Merinopoulo E","year":"2020","unstructured":"Merinopoulo E, Nordstrom B, Huse S, et al. Treatment patterns and clinical outcomes of patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitor monotherapy in the first-line setting in community-based practices in the United States. Pharmacoepidemiol Drug Saf. 2020;29(S3):3\u2013634.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041041"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e21184"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1298603"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0061"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.834761"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02885"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21638"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.1268"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.1884"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010674"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1924"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30030247"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194846"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000340"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122935"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000490"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3591"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1510278"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(21)01952-3"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100397"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2020.1781249"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202310_33949"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2024.20309"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2025.42746"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221079356"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108422"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.02.001"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1237"},{"key":"e_1_3_5_112_1","unstructured":"Duarte-Salles TPJ Barchuk A Ravent\u00f3s B et al. Darwin EU\u00ae \u2013 Overall survival in patients with locally advanced or metastatic non-small cell lung cancer treated with selected immunotherapies as first line of treatment. 2025 May."},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2443"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e18731"},{"issue":"3","key":"e_1_3_5_115_1","first-page":"3","article-title":"Treatment patterns and clinical outcomes of patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitors in combination with chemotherapy in the first-line setting in community-based practices in the United States","volume":"29","author":"Merinopoulou E","year":"2020","unstructured":"Merinopoulou E, Nordstrom B, Huse S, et al. Treatment patterns and clinical outcomes of patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitors in combination with chemotherapy in the first-line setting in community-based practices in the United States. Pharmacoepidemiol Drug Saf. 2020;29(S3):3\u2013634.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.999343"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0313"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88453-8"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100444"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(21)01950-X"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.1241"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(23)00306-4"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108985"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1865653"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03359-2"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.48095\/ccko2025192"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100509"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15304"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-556"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.12.011"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3649-24"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2025.01.014"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1177\/1932296819832653"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.09.017"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02613-9"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107318"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-03072-1"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00228-2"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071804"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01164-2"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1160144"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101921"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4960"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2026.106065"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.05.010"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1111\/hex.13457"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00177"},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.6901"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.07.006"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00718"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.03.10"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231195600"},{"key":"e_1_3_5_154_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1080998"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2709201","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2026.2709201","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2709201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:51:59Z","timestamp":1787651519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2026.2709201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":155,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,8,9]]}},"alternative-id":["10.1080\/14796694.2026.2709201"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2026.2709201","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}